Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 1
2021 pubmed 7 citations

A drug candidate for Alzheimer's and Huntington's disease, PBT2, can be repurposed to render Neisseria gonorrhoeae susceptible to natural cationic antimicrobial peptides.

Jen. Freda E-C FE; El-Deeb. Ibrahim M IM; Zalucki. Yaramah M YM; Edwards. Jennifer L JL; Walker. Mark J MJ; von Itzstein. Mark M; Jennings. Michael P MP

Key Findings

  • PBT2 combined with zinc makes the peptide LL‑37 synergistically kill resistant N. gonorrhoeae
  • The combo also restores tetracycline effectiveness against resistant strains
  • Proteomic analysis suggests PBT2 disrupts bacterial membrane integrity and increases protein misfolding

Practical Outcomes

  • For most biohackers this isn’t a direct protocol to try; it’s a proof‑of‑concept that could lead to new treatments for resistant infections. Until clinical trials confirm safety and dosing, it’s not actionable for personal health optimization.

Summary

Scientists found that a drug called PBT2, originally being studied for Alzheimer’s, can help the body’s natural antimicrobial peptide LL‑37 kill antibiotic‑resistant gonorrhea bacteria, and it also makes the bacteria more sensitive to the antibiotic tetracycline. This works by messing up the bacteria’s membrane and causing protein problems, but it’s a lab finding, not a ready‑to‑use health hack.

Abstract

Neisseria gonorrhoeae is a Gram-negative bacterial pathogen that causes gonorrhoea. No vaccine is available to prevent gonorrhoea and the emergence of MDR N. gonorrhoeae strains represents an immediate public health threat. To evaluate whether PBT2/zinc may sensitize MDR N. gonorrhoeae to natural cationic antimicrobial peptides. MDR strains that contain differing resistance mechanisms against numerous antibiotics were tested in MIC assays. MIC assays were performed using the broth microdilution method according to CLSI guidelines in a microtitre plate. Serially diluted LL-37 or PG-1 was tested in combination with a sub-inhibitory concentration of PBT2/zinc. Serially diluted tetracycline was also tested with sub-inhibitory concentrations of PBT2/zinc and LL-37. SWATH-MS proteomic analysis of N. gonorrhoeae treated with PBT2/zinc, LL-37 and/or tetracycline was performed to determine the mechanism(s) of N. gonorrhoeae susceptibility to antibiotics and peptides. Sub-inhibitory concentrations of LL-37 and PBT2/zinc synergized to render strain WHO-Z susceptible to tetracycline, whereas the killing effect of PG-1 and PBT2/zinc was additive. SWATH-MS proteomic analysis suggested that PBT2/zinc most likely leads to a loss of membrane integrity and increased protein misfolding and, in turn, results in bacterial death. Here we show that PBT2, a candidate Alzheimer's and Huntington's disease drug, can be repurposed to render MDR N. gonorrhoeae more susceptible to the endogenous antimicrobial peptides LL-37 and PG-1. In the presence of LL-37, PBT2/zinc can synergize with tetracycline to restore tetracycline susceptibility to gonococci resistant to this antibiotic.

Study Information

Provider

pubmed

Year

2021

Date

2021-10-11T00:00:00.000Z

DOI

10.1093/jac/dkab291

Citations

7

References

24